Find clinical trials in your area

Search by disease and location to discover available clinical trials matching your criteria.

Matched clinical trials

  • Study of drug combination therapy in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma using odronextamab, loncastuximab tesirine and rituximab

    Recruiting

    4 1 1 1
    Austria Belgium France The Netherlands Spain Sweden
  • Study on Axicabtagene Ciloleucel for Patients with Late Relapse of Diffuse Large B-Cell Lymphoma

    Recruiting

    2 1 1 1
    Spain
  • Study on the Safety and Effectiveness of MB-CART2019.1, Fludarabine, and Cyclophosphamide in Children with Relapsed or Refractory B Cell Neoplasms

    Recruiting

    2 1 1 1
    France Germany Italy The Netherlands
  • Study on MB-CART2019.1 for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible for High-Dose Chemotherapy and Stem Cell Transplantation

    Recruiting

    2 1 1 1
    Austria Belgium Croatia Czechia Finland France +9
  • Long-Term Safety Study of MB-CART19.1, MB-CART20.1, and Zamtocabtagene Autoleucel for Patients with Advanced Melanoma or B-Cell Malignancies

    Recruiting

    1 1 1
    Germany
  • Study of MEN1703 and Glofitamab for Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

    Recruiting

    2 1 1 1 1
    France Poland Spain
  • A Study Testing the Safety of CD19-Targeted CAR T-Cell Therapy in Children and Young Adults with Relapsed or Refractory B-Cell Cancers

    Not yet recruiting

    1 1 1
    Investigated drugs:
    The Netherlands
  • Study on the Safety and Effectiveness of MB-CART2019.1 for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma

    Not yet recruiting

    2 1 1 1
    Croatia Hungary
  • Study on the Safety and Effectiveness of Glofitamab and Obinutuzumab for Patients with Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma

    Not recruiting

    2 1 1 1
    Belgium Czechia Denmark Finland France Italy +2
  • Study on the Safety and Effectiveness of Mosunetuzumab and Atezolizumab for Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia

    Not recruiting

    1 1 1 1
    Germany Spain